Literature DB >> 18326583

Topological mapping of the asymmetric drug binding to the human ether-à-go-go-related gene product (HERG) potassium channel by use of tandem dimers.

Toshihiko Myokai1, Sunghi Ryu, Hirofumi Shimizu, Shigetoshi Oiki.   

Abstract

The human ether-à-go-go related gene product (HERG) channel is essential for electrical activity of heart cells, and block of this channel by many drugs leads to lethal arrhythmias. Tyr(652) and Phe(656) of the sixth transmembrane helix are candidates for the drug binding site. In the tetrameric HERG channel, a drug with asymmetric structure should interact unevenly with multiple residues from different subunits. To elucidate the topology of the drug-binding site, we constructed tandem dimers of HERG channels and the aromatic Tyr(652) and Phe(656) residues were replaced by alanine singly or doubly. Eight types of HERG channels, including homotetrameric mutants, having different numbers and arrangements of aromatic residues at the blocking site, were studied. Effects of cisapride on channels expressed in Xenopus laevis oocytes were examined electrophysiologically. The inhibition constants (K(i)) were increased significantly as the diagonal Tyr(652) were deleted, whereas those for the diagonal Phe(656)-deleted mutant were not changed. These results suggest that Tyr(652) residues from adjacent subunits contributed to the binding. Two types of double mutants of tandem dimers showed significantly distinct affinities, suggesting that the coexistence of Tyr(652) and Phe(656) on a subunit in diagonal position is crucial to having a high affinity. Thermodynamic double-mutant cycle analyses revealed interactions between Tyr(652) and Phe(656) upon binding. The kinetics and voltage-dependence of blocking suggested transitions of the binding site from low to high affinity. These approaches using a set of mutant HERG channels gave a dynamic picture of the spatial arrangements of residues that contribute to the drug-channel interaction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18326583     DOI: 10.1124/mol.107.042085

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  7 in total

Review 1.  Revealing the structural basis of action of hERG potassium channel activators and blockers.

Authors:  Matthew Perry; Michael Sanguinetti; John Mitcheson
Journal:  J Physiol       Date:  2010-07-19       Impact factor: 5.182

2.  Predicting the potency of hERG K⁺ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models.

Authors:  Yayu Tan; Yadong Chen; Qidong You; Haopeng Sun; Manhua Li
Journal:  J Mol Model       Date:  2011-06-10       Impact factor: 1.810

3.  Non-sedating antihistamines block G-protein-gated inwardly rectifying K+ channels.

Authors:  I-Shan Chen; Chang Liu; Michihiro Tateyama; Izhar Karbat; Motonari Uesugi; Eitan Reuveny; Yoshihiro Kubo
Journal:  Br J Pharmacol       Date:  2019-07-10       Impact factor: 8.739

4.  Differential hERG ion channel activity of ultrasmall gold nanoparticles.

Authors:  Annika Leifert; Yu Pan; Anne Kinkeldey; Frank Schiefer; Julia Setzler; Olaf Scheel; Hera Lichtenbeld; Günter Schmid; Wolfgang Wenzel; Willi Jahnen-Dechent; Ulrich Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-29       Impact factor: 11.205

5.  Investigating the state dependence of drug binding in hERG channels using a trapped-open channel phenotype.

Authors:  Samrat Thouta; Garman Lo; Lukas Grajauskas; Tom Claydon
Journal:  Sci Rep       Date:  2018-03-21       Impact factor: 4.379

6.  Modification by KCNE1 variants of the hERG potassium channel response to premature stimulation and to pharmacological inhibition.

Authors:  Chunyun Du; Aziza El Harchi; Henggui Zhang; Jules C Hancox
Journal:  Physiol Rep       Date:  2013-11-29

7.  Structural implications of hERG K+ channel block by a high-affinity minimally structured blocker.

Authors:  Matthew V Helliwell; Yihong Zhang; Aziza El Harchi; Chunyun Du; Jules C Hancox; Christopher E Dempsey
Journal:  J Biol Chem       Date:  2018-03-15       Impact factor: 5.157

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.